[The TECOS, EXAMINE and SAVOR studies--how do they differ and what are their outcomes?].

Abstract

The treatment of diabetes mellitus type 2 is effective, but still is not optimal. DPP4 inhibitors (gliptins) are a new group of peroral antidiabetic drugs. The third clinical mortality study with gliptins in patients with diabetes mellitus type 2 was finished in 2015. The studies are known under acronym TECOS, SAVOR and EXAMINE and the tested drugs are sitagliptin, saxagliptin and alogliptin. The studies included about 37,000 patients. The studies confirmed the cardiovascular safety of the DPP4 inhibitors, but the question about increased heart failure remains open. The effectiveness of lowering glycaemia (glycated haemoglobin) was confirmed and also the pancreatic safety is confirmed.

• Authors: Jindřich Špinar, Lenka Špinarová, Jiří Vítovec
• Journal: Vnitrni lekarstvi (Vnitr Lek) Vol. 61 Issue 11 Pg. 976-83 (Nov 2015) ISSN: 0042-773X [Print] Czech Republic
• Vernacular Title: Studie TECOS, EXAMINE a SAVOR--čím se liší a co přinášejí?
• PMID: 26652787 (Publication Type: Journal Article, Review)

Chemical References

• Blood Glucose
• Dipeptides
• Dipeptidyl-Peptidase IV Inhibitors
• Glycated Hemoglobin A
• Hypoglycemic Agents
• Piperidines
• Uracil
• saxagliptin
• alogliptin
• Adamantane
• Sitagliptin Phosphate

Topics

• Adamantane (analogs & derivatives, therapeutic use)
• Blood Glucose (drug effects)
• Diabetes Mellitus, Type 2 (blood, drug therapy)
• Dipeptides (therapeutic use)
• Dipeptidyl-Peptidase IV Inhibitors (therapeutic use)
• Glycated Hemoglobin
• Heart Failure (drug therapy)
• Humans
• Hypoglycemic Agents
• Piperidines (therapeutic use)
• Sitagliptin Phosphate (therapeutic use)
• Uracil (analogs & derivatives, therapeutic use)